insitro
Data as of .
Company facts
-
Founded
2018
-
Headquarters
United States (South San Francisco, CA)
-
Total funding
$750M+
Latest funding round
- Round
- Series C
- Date
- Mar 15, 2021
- Amount
- $400M
- Lead investor
- CPP Investments
Drug discovery partners
3 pharma. Pharma here means a company with approved products and roughly $1B or more in annual revenue.
-
AstraZeneca Pharma
Discovery collaboration and license,
$40M upfront ($1.5B total potential)
-
Bristol Myers Squibb Pharma
Expanded collaboration,
Terms not disclosed
-
Eli Lilly Pharma
ML models for small-molecule design on Lilly data (TuneLab),
Terms not disclosed
Recent news
-
AstraZeneca collaboration for AI discovery in MASH and cardiomyopathies; $40M upfront plus milestones (third-party posts say up to about $1.46B)
-
Biotechs in Lilly's TuneLab network can now use ML models insitro built with Lilly
-
Appoints Hideo Makimura as Chief Medical Officer
-
Shares in vivo data from its wholly owned ALS oligonucleotide program
-
Bristol Myers Squibb collaboration expanded
Confirmed means the company, a partner or a filing said it. Reported means a third party said it. This section sits outside the Pharma AI Tracker.
Spot an error? Tell me and I'll fix it.